

MEDICAL ONCOLOGY

PAPER – II

Time : 3 hours

MED.ONCO./D/17/17/II

Max. Marks : 100

Important instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. Describe about breast cancer under following headings. 3+7
 - a. Her 2 neu gene testing: Immunohistochemistry versus FISH.
 - b. Use of Her-2 neu targeted therapy in neo-adjuvant, adjuvant and metastatic setting.
2.
 - a. List the investigation in a suspected case of chronic myeloproliferative disease (CMPD)
 - b. Molecular biology of Ph negative CMPD
 - c. Ruxolitinib: Indications and side effects3+3+4
3.
 - a. Lugano staging of non Hodgkin's lymphoma
 - b. Describe criteria for response assessment in lymphoma4+6
4.
 - a. Pathology of gastric carcinoma
 - b. Treatment both chemotherapy and targeted for unresectable gastric carcinoma4+6
5.
 - a. List various cytotoxic agents associated with severe emesis.
 - b. Prevention and treatment of chemotherapy induced nausea and vomiting with various agents.
 - c. Explain their mechanism of action and side effects.3+4+3
6.
 - a. Pathology of medulloblastoma.
 - b. Molecular classification of medulloblastoma
 - c. Staging of medulloblastoma and salient investigations for its staging.3+3+4

P.T.O.

MEDICAL ONCOLOGY

PAPER – II

- | | | |
|-----|---|-------|
| 7. | a. Role of check point inhibitors in non small cell lung cancer (NSCLS) | 3+4+3 |
| | b. Algorithm for first time treatment of metastatic NSCLS | |
| | c. Role of ceritinib and alectinib in NSCLC with brain metastasis | |
| 8. | a. Pathology and staging of prostate cancer. | 5+2+3 |
| | b. What is androgen resistant prostate cancer? | |
| | c. Chemotherapy indications in prostate cancer with 'supporting indications'. | |
| 9. | a. Pathology of Rhabdomyosarcoma. | 4+3+3 |
| | b. Cytogenetic/ Translocation studies in sarcoma: mention tumours where it is useful in diagnosis | |
| | c. Huvos grading in osteosarcoma | |
| 10. | a. Grading of pancreatic neuro-endocrine tumours. | 3+4+3 |
| | b. Utility of nuclear medicine for diagnosis and treatment of neuroendocrine tumour. | |
| | c. Chemotherapy of neuroendocrine tumor. | |
